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Abstract  
Synergy between Yttrium-90 (90Y) and drugs was investigated. Viability of HepaRG 
(hepatocellular carcinoma) and HuCCT1 (cholangiocarcinoma) cells was studied 
through a tetrazolium dye reduction (MTT) assay. A combination index (CI) was 
calculated, CI<1 denoting synergy and CI>1 antagonism. In HepaRG, gemcitabine 
showed synergy with 90Y (CI=0.70 [0.65-0.75]), while oxaliplatin (CI=1.15 [1.081.21]), 
paclitaxel (CI=1.26 [1.15-1.37]) and sorafenib (CI=1.77 [1.65-1.89]) showed 
antagonism. In HuCCT1, gemcitabine (CI=0.54 [0.50-0.58]) and oxaliplatin (CI=0.86 
[0.82-0.90]) showed synergy with 90Y, while paclitaxel (CI=1.18 [1.09-1.27]) and 
sorafenib (CI=1.21 [1.12-1.30]) showed antagonism. These results suggest that 
gemcitabine and oxaliplatin should be tested in combination with 
90Yradioembolization in liver cancer.  
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Introduction:  
Yttrium-90 (90Y)-radioembolization, or Selective Internal Radiation Therapy (SIRT) is 
an emerging treatment modality for liver malignancies. It showed similar results as 
transarterial chemoembolization in intermediate hepatocellular carcinoma (HCC) (1).  
Some series also report promising activity in intrahepatic cholangiocarcinoma (ICC) 
(2). SIRT is used as monotherapy in primary liver cancer. However, it might be 
hypothesized that combination with systemic treatments may be beneficial by treating  
micrometastases, but also potentially by enhancing efficiency of SIRT through a 
synergistic effect on the primary tumor. However, these potential synergy might also 
lead to a risk of increased toxicity. SIRT is now being tested in metastatic colorectal 
cancer with concurrent chemotherapy, rather than alone (e.g. in the EPOCH trial, 
clinicaltrials.gov identifier NCT01483027, the FoxfireGlobal trial, NCT01721954, and 
the SIRFLOX trial, NCT00724503).  
In advanced HCC, the only validated systemic agent is sorafenib, a tyrosine-kinase 
inhibitor targeting VEGFR, RAF and other kinases. However, systemic chemotherapy 
could be used with some evidence of efficacy. The combination of gemcitabine and 
oxaliplatin showed some activity in advanced HCC (3). In advanced ICC, the 
standard systemic treatment consists of a combination of gemcitabine and a platinum 
compound, but response rates are lower than 25% (4). Gemcitabine, oxaliplatin and 
paclitaxel have been shown to exhibit a synergistic effect with external beam 
radiotherapy, and some clinical applications exist, notably in pancreatic cancer (5). 
2  
Paclitaxel is used as a radiosensitizing agent for lung cancer, and could thus be 
tested as potential radiosensitizing agent for primary liver cancers (6).  
Sorafenib, gemcitabine, oxaliplatin and paclitaxel would thus be relevant drugs to test 
in combination with SIRT for primary liver malignancies. To our knowledge, no data 
were reported as regard to synergy between antineoplastic drugs and 1Y.  The 
purpose of the study was thus to identify potential synergy between antineoplastic 
drugs and 90Y in primary liver cancer cell lines.  
Materials and methods  
Cell lines  
HepaRG was used as a hepatocarcinoma cell line, and HuCCT1 as a 
cholangiocarcinoma cell line (7,8). HepaRG cells were grown in William's E medium 
supplemented with 10% fetal bovine serum (FBS), 100U/mL penicillin, 100µg/mL 
streptomycin, 5µg/mL insulin, and 50µM hydrocortisone hemisuccinate. HuCCT1 
cells were provided by the RIKEN BioResource Centre, Japan, and were grown in 
RPMI 1640 medium supplemented with 10% FBS, 100U/mL penicillin, 100µg/mL 
                                            
1 Y was provided with an activity of 740MBq (20mCi) in sterile condition as Yttrium 
chloride and diluted in the cell culture medium to reach the selected activity, 
measured using a Capintec CRC-127R well-counter. Sorafenib was diluted in 
dimethylsulfoxyde at 10 nM. Gemcitabine was diluted in 0.9% Sodium Chloride at a 
stock concentration of 38mg/mL. Oxaliplatin was diluted in 5% glucose at a stock  
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streptomycin and 2mM L-glutamine. HepG2 and Huh28 cells were also studied as 
confirmatory cell lines for hepatocarcinoma and cholangiocarcinoma, respectively.  
Treatments  
concentration of 5mg/mL. Paclitaxel was diluted in 0.9% Sodium Chloride at a stock 
concentration of 6mg/mL. Each drug was subsequently diluted in the cell culture 
medium.  
Cell viability assay  
Twenty-four hours after seeding, cells were treated with 90Y and/or drugs for 72 
hours. To measure cell viability, the 3-(4,5-dimethylthiazol-2-yl)-
2,5diphenyltetrazolium (MTT) assay was used. The reduction of MTT into formazan 
salts in mitochondria of viable cells produces a coloration that could be measured by 
spectrophotometry, the coloration being linearly proportionate to the number of viable 
cells (9). Percentages of cell viability assessed by the MTT assay were then plotted 
against drug concentrations and 90Y activities to evaluate concentrations inducing a  
20% to 50%-reduction in cell viability, which was used to test in combination assays. 
This range of reduction of cell viability was chosen to be able to detect significant 
additivity or synergy: a higher reduction in cell viability in monotherapy would have 
led to insufficient viability in combination to distinguish synergy from additivity, and a 
lower reduction would have made difficult to detect any additivity. Every assay was 
performed in triplicate, and every experiment was repeated three times.  
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Combination index  
A combination index (CI) was calculated to identify additive or synergistic 
(supraadditive) effects. CI is the ratio between the effect observed for the 
combination and the theoretical additive effect calculated (10). The theoretical 
additive effect (TAE) was calculated by multiplying the individual effect reported with 
each drug used separately. CI equals to 1 denoted additivity, <1 denoted synergy 
and >1 denoted antagonism. Ninety-five percent confidence intervals were calculated 
to determine statistical significance.  
Results  
First, the effect on cell viability following each treatment was studied individually to 
select activities and concentrations suitable to identify additive or synergistic effects 
in combination assays (Table 1 and Figure E1). Higher activity for 1Y was used for 
HuCCT1 cells as compared with HepaRG cells because no inhibitory effect was seen 
                                            
1 Y (CI=1.15 [1.08-1.21]), as was paclitaxel (CI=1.26 [1.15-1.37]), and sorafenib  
(CI=1.77 [1.65-1.89]). Results regarding HuCCT1 cells are reported on Figure 2. 
There was a clear synergy between gemcitabine and 90Y (CI=0.54 [0.50-0.58]), as 
well as between oxaliplatin and 90Y (CI=0.86 [0.82-0.90]). However, there was an 
antagonist effect between paclitaxel and 90Y (CI=1.18 [1.09-1.27]), and between 
sorafenib and 90Y (CI=1.21 [1.12-1.30]). Similar results were obtained using HepG2 
and Huh28 cell lines (Figures E2 and E3).  
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at 1.11 MBq for HuCCT1 while an excessive inhibitory effect to properly assess 
additivity was seen at 3.7 MBq for HepaRG.  
Then, the effects of the combination of 90Y with the different drugs were evaluated in 
both cell lines. Results concerning HepaRG cells are reported on Figure 1.  
Gemcitabine had a clear synergistic effect when combined with 90Y, with a CI=0.70  
[95% confidence interval: 0.65-0.75]. Oxaliplatin was antagonist when combined with 
Discussion  
As most of the patients eventually progress following SIRT, with a median time to 
progression between 8 to 14 months in large HCC series (1), development of 
strategies to improve efficacy are warranted. Using systemic treatment in 
combination with SIRT for synergy is potentially such a strategy.  
The results presented here showed a strong synergistic effect between gemcitabine 
and 90Y in both cell lines. This is consistent with the known radiosensitizing effect of 
the drug (5). While synergy between oxaliplatin and 90Y was shown in the 
cholangiocarcinoma cell lines, it was not the case in the HCC cell lines. By contrast, 
paclitaxel and sorafenib showed antagonism with 90Y. However, the design of this in 
vitro study could not address whether the synergistic combinations could also 
increase liver toxicity.  
These results provide first preclinical evidence to study the combination of 
gemcitabine and oxaliplatin with 90Y-SIRT in primary liver malignancies. Gemcitabine 
and 5-fluorouracile were previously studied in combination with low dose of external 
beam radiation (11), and cisplatin and 5-fluorouracile were shown to have synergistic 
effect with Iodine-131 (12). With Rhenium-188, 5-fluorouracile had only a transient 
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supra additive effect (13) and sorafenib showed evidence of synergy (14). All of these 
data suggest that systemic treatments may enhance efficacy of SIRT.  
To date, sorafenib is the only drug tested in combination with SIRT in HCC. The 
rationale for such combination lies on proven activity of both treatment used as 
monotherapy, and on potential effects of SIRT on secretion of angiogenic factors  
(15). However, the results of anti-angiogenic drugs in the tumoral vasculature may be 
difficult to predict, and little is known whether it would have a beneficial or a 
detrimental effect on tumoral uptake of microspheres. However, the results of the 
present study suggest that combination of sorafenib with 90Y might have an 
antagonist effect on tumoral cell growth itself, but its design did not address the effect 
on angiogenesis.  
This study has some limitations. The conclusions drawn would have been reinforced 
by replication in an in vivo model. It is difficult to correlate activity received in an in 
vitro model and activity received by the tumor in patients, but the activity received in 
this study are approximately 1000 times less than activity injected in an 
approximately 1000 times greater volume in clinics, so might probably be viewed as  
“in a clinical range”. The study design did not address the question of angiogenesis, 
which is one of the mechanisms of action of sorafenib, and the interactions between 
SIRT, angiogenesis and hypoxia. The potential increase of toxicity could also not be 
studied in vitro.  
In conclusion, this study supports the use of gemcitabine and oxaliplatin in 
combination with SIRT in HCC and ICC, but not the use of paclitaxel or sorafenib. 
Clinical trial of combination of gemcitabine-platinum compounds with SIRT are 
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warranted on HCC and ICC, and a phase II study combining glass microsphere SIRT 
and gemcitabine-cisplatin in ICC is now recruiting patients (Misphec Study,  
NCT01912053).  
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Figure legends  
 
Figure 1: Cell viability following treatment of HepaRG cells with gemcitabine, 
oxaliplatin, paclitaxel or sorafenib alone or in combination with 90Y. Ctrl: Control;  
Gem: Gemcitabine; 90Y: Yttrium-90; Oxa: Oxaliplatin; Pac: Paclitaxel; Sor: Sorafenib; 
TAE: Theoretical Additive Effect. The TAE column is the calculated product of cell 
viability following the two individual treatments. It reflects the value corresponding to 
a Combination Index of 1 (perfect addition). Value of the control is based on 
normalization. * denotes p<0.05.  
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Figure 2: Cell viability following treatment of HuCCT1 cells with gemcitabine, 
oxaliplatin, paclitaxel or sorafenib alone or in combination with 90Y. Ctrl: Control;  
Gem: Gemcitabine; 90Y: Yttrium-90; Oxa: Oxaliplatin; Pac: Paclitaxel; Sor: Sorafenib; 
TAE: Theoretical Additive Effect. The TAE column is the calculated product of cell 
viability following the two individual treatments. It reflects the value corresponding to 
a Combination Index of 1 (perfect addition). Value of the control is based on 
normalization. * denotes p<0.05.  
Figure E1: Cell viability following treatments of HepaRG (upper line) and HuCCT1  
(lower line) with 90Y, gemcitabine, oxaliplatin, paclitaxel and sorafenib monotherapy. 
Isobars represent 95% confidence intervals. These dose-response assessment were 
used to select the dose inducing 20 to 50%-decrease of cell viability, to test in the 
combination experiments.  
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Figure E2: Cell viability following treatment of HepG2 cells with gemcitabine, 
oxaliplatin, paclitaxel or sorafenib alone or in combination with 90Y. Ctrl: Control;  
Gem: Gemcitabine; 90Y: Yttrium-90; Oxa: Oxaliplatin; Pac: Paclitaxel; Sor: Sorafenib; 
TAE: Theoretical Additive Effect. The TAE column is the calculated product of cell 
viability following the two individual treatments. It reflects the value corresponding to 
a Combination Index of 1 (perfect addition). Value of the control is based on 
normalization. * denotes p<0.05.  
Figure E3: Cell viability following treatment of Huh28 cells with gemcitabine, 
oxaliplatin, paclitaxel or sorafenib alone or in combination with 90Y. Ctrl: Control;  
Gem: Gemcitabine; 90Y: Yttrium-90; Oxa: Oxaliplatin; Pac: Paclitaxel; Sor: Sorafenib; 
TAE: Theoretical Additive Effect. The TAE column is the calculated product of cell 
viability following the two individual treatments. It reflects the value corresponding to 
a Combination Index of 1 (perfect addition). Value of the control is based on 
normalization. * denotes p<0.05.  
